These eight projects took top marks in the three office subcategories for this year's Best Real Estate Deals awards program.

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® ...

The stock's fall snapped a four-day winning streak.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Shares of Incyte Corp. INCY rose 1.39% to $62.78 Monday, on what proved to be an all-around positive trading session for the ...

Incyte’s The Unseen Journey illustrates the hidden emotional and physical toll of myeloproliferative neoplasms (MPNs), a ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Morgan Stanley lowered the firm’s price target on Incyte (INCY) to $65 from $69 and keeps an Equal Weight rating on the shares. Based on the ...

Researchers from Mass General Brigham developed olfactory tests—in which participants sniff odor labels that have been placed on a card—to assess people’s ability to discriminate, identify and ...

Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

The Communication Authority of Kenya (CAK) also reduced the rate from Ksh0.99 ($0.0076) per minute to Ksh0.41 ($0.0031) per ...